MONTE ROSA THERAPEUTICS INC. - COMMON STOCK

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

10 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

13 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

11 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

11 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

05 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

26 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

13 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

07 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

28 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

19 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

08 Aug 2024 07:00:02 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

08 Jul 2024 08:36:57 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

27 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

14 Jun 2024 08:45:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Leadership Team Promotions

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

21 May 2024 07:00:00 By Nasdaq GlobeNewswire